May 20, 2019

Important Notice/Clarification Regarding Scope of Practice for the Administration of Radioactive Material by the Nuclear Medicine Technologists

A number of health professionals have expressed their concerns regarding the Scope of Practice for the Administration of Radioactive Material by Nuclear Medicine Technologists. This notice is intended to provide more detail regarding the scope of practice for the administration of radioactive material by Nuclear Medicine Technologists.

The laws and regulations governing the administration of radioactive material by Nuclear Medicine Technologists are not intended to exclude the use of cold kits by technologists. Nor were these intended to prevent Nuclear Medicine Technologists from administering physiologically inactive agents that are normally considered part of the practice of nuclear medicine technology. For example, nonradioactive components of cold kits such as pyrophosphate for the in vitro or in vivo labeling of red blood cells, may be administered by Nuclear Medicine Technologists.

The parenteral administration of physiologically active agents such as furosemide or dipyridamole by Nuclear Medicine Technologists is not addressed by the Nuclear Medicine Technology Laws (Health and Safety Code sections 107150 et seq.) and regulations (17 CCR sections 30500 et seq.). Therefore, Nuclear Medicine Technologists performing such administrations within their scope of practice are acting under authority of a medical practice law other than the Nuclear Medicine Technology Laws.

In addition, nuclear medicine technology laws and regulations permit technologists to withdraw blood in the performance of their duties.

Sincerely,

Signature on file

Gonzalo L. Perez, Chief
Radiologic Health Branch